Melt-processed imatinib dosage form

US8841303B2 · kind B2 · utility

Assignees

• Abb Vie Deutschland Gmbh & Co. KG · DE
• Novartis AG · CH

Inventors

• Jorg Breitenbach · Mannheim, DE
• Norbert Steiger · Lingenfeld, DE
• Harald Hach · Bad Bergzabern, DE
• Ulrich Westedt · Schriesheim, DE
• Martin Knobloch · Schifferstadt, DE
• Ralf Altenburger · Eimeldingen, DE
• Nicoletta Loggia · Basel, CH
• Jorg Ogorka · Steinen, DE

Key dates

• Filing date: Nov 8, 2007
• Grant date: Sep 23, 2014
• Expiry date: Aug 22, 2029

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/02
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides a dosage form, comprising a melt-processed mixture of (a) a pharmaceutically effective amount of imatinib or a salt thereof, (b) at least one polymeric binder, and (c) at least one pharmaceutically acceptable non-ionic surfactant. The invention provides imatinib dosage forms with high drug loading which can be prepared in a simple and efficient manner, imatinib dosage forms from which the active principle is released in an essentially pH-independent fashion, and extended release imatinib dosage forms.